■估计的峰值耗氧量(Vo2peak)广泛用于肿瘤学;但是,估计的Vo2peak方程是在非癌症环境中开发的。
■这项研究的目的是评估原发性乳腺癌女性中估计的Vo2peak的有效性,并建立肿瘤学特异性估计的Vo2peak方程。
■Vo2peak是在380次心肺运动试验中直接测量的(TrueOne2400,ParvoMeds),这些试验是针对先前接受过乳腺癌治疗的女性(平均年龄:59±10岁;治疗后3.1±1.2岁)。美国运动医学学院(ACSM)健身登记和锻炼的重要性国家数据库(朋友),和心力衰竭(HF)-FRIEND方程用于估计Vo2peak。使用患者和峰值(Oncpeak)或次最大(Oncsub)运动测试特征开发新的方程式。
■测得的Vo2peak与估算的Vo2peak之间的中值差异为7.0mLO2·kg-1·min-1,3.9mLO2·kg-1·min-1和-0.2mLO2·kg-1·min-1,朋友,和HF-朋友,分别。在测量值的±3.5mLO2·kg-1·min-1范围内,估计的Vo2峰值为70(18%),164(43%),ACSM为306(81%),朋友,和HF-朋友,分别。Oncpeak和OncSub模型包括体重指数,年龄,化疗或放疗史,测量的峰值心率,以及跑步机等级和/或速度。测得的Vo2peak与估计的Vo2peak之间的中值差异为0.02mLO2·kg-1·min-1(Oncpeak)和-0.2mLO2·kg-1·min-1(Oncsub)。86%(n=325)和76%(n=283)的Vo2峰值估计在Oncpeak和Oncsub测得的Vo2峰值的±3.5mLO2·kg-1·min-1内,分别。
■HF-FRIEND或肿瘤学特异性方程可用于在无法进行心肺运动试验的情况下估计先前接受过乳腺癌治疗的患者的Vo2peak。(比较线性和非线性有氧训练对可手术乳腺癌女性的影响的试验[EXCITE];NCT01186367。
UNASSIGNED: Estimated peak oxygen consumption (Vo2peak) is widely used in oncology; however, estimated Vo2peak equations were developed in noncancer settings.
UNASSIGNED: The aim of this study was to evaluate the validity of estimated Vo2peak in women with primary breast cancer and to develop oncology-specific estimated Vo2peak equations.
UNASSIGNED: Vo2peak was directly measured (TrueOne 2400, Parvo Medics) during 380 cardiopulmonary exercise tests in women previously treated for breast cancer (mean age: 59 ± 10 years; 3.1 ± 1.2 years post-therapy). The American College of Sports Medicine (ACSM), the Fitness Registry and the Importance of Exercise National Database (FRIEND), and heart failure (HF)-FRIEND equations were used to estimate Vo2peak. New equations were developed using patient and peak (Oncpeak) or submaximal (Oncsub) exercise test characteristics.
UNASSIGNED: The median differences between measured and estimated Vo2peak were 7.0 mL O2·kg-1·min-1, 3.9 mL O2·kg-1·min-1, and -0.2 mL O2·kg-1·min-1 for ACSM, FRIEND, and HF-FRIEND, respectively. The number of estimated Vo2peak values within ±3.5 mL O2·kg-1·min-1 of the measured values was 70 (18%), 164 (43%), and 306 (81%) for ACSM, FRIEND, and HF-FRIEND, respectively. The Oncpeak and OncSub models included body mass index, age, a history of chemotherapy or radiation, the peak measured heart rate, and the treadmill grade and/or speed. The median differences between measured and estimated Vo2peak were 0.02 mL O2·kg-1·min-1 (Oncpeak) and -0.2 mL O2·kg-1·min-1 (Oncsub). Eighty-six percent (n = 325) and 76% (n = 283) estimated Vo2peak values were within ±3.5 mL O2·kg-1·min-1 of the measured Vo2peak values for Oncpeak and Oncsub, respectively.
UNASSIGNED: HF-FRIEND or oncology-specific equations could be applied to estimate Vo2peak in patients previously treated for breast cancer in settings where cardiopulmonary exercise tests are not available. (Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer [EXCITE]; NCT01186367.